Viewing data from:

OLINVYK

NDA

OLICERIDINE | N210730 | TREVENA INC

3 strengths5 unique patents0 unique exclusivities

Patent Timeline

5 unique patents by expiration date

Active (5)Today

2027

2028

2029

2030

2031

2032

Today

Mar. 23, 2032

Mar. 23, 2032

Mar. 23, 2032

Mar. 23, 2032

Mar. 23, 2032

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

1 trial from ClinicalTrials.gov, 1 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Effect of Oliceridine Analgesia on Postoperative Nause and Vomiting NCT06411665	Phase 4	Completed	Peking University First Hospital	252	2024-07-02 → 2025-04-14

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Approval Letters

4 letters from Drugs@FDA

Date	Submission	Document
Dec 23, 2025	SUPPL -4	View Letter (PDF)
Dec 19, 2023	SUPPL -2	View Letter (PDF)
Mar 5, 2021	SUPPL -1	View Letter (PDF)
Aug 10, 2020	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — 1MG/ML (1MG/ML)

RLD

5 patents0 exclusivities▴

SOLUTION;INTRAVENOUS | Approved: Oct 30, 2020

Patents (5)

Patent #	Expiration	PED	Drug Substance	Drug Product	Delist
8835488	Mar 23, 2032	—	Yes	Yes	—
9309234	Mar 23, 2032	—	Yes	Yes	—
9642842	Mar 23, 2032	—	—	Yes	—
11077098	Mar 23, 2032	—	Yes	Yes	—
11931350	Mar 23, 2032	—	Yes	—	—

#002 — 2MG/2ML (1MG/ML)

RLD

5 patents0 exclusivities▾

SOLUTION;INTRAVENOUS | Approved: Oct 30, 2020

#003 — 30MG/30ML (1MG/ML)

RLD

5 patents0 exclusivities▾

SOLUTION;INTRAVENOUS | Approved: Oct 30, 2020